All Posts By

Smartkarma Daily Briefs

Daily Brief South Korea: Korea Stock Exchange KOSPI 200, S.M.Entertainment Co and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Confirmed: Conditions & Schedule of Block Deals Pre-Disclosure Rules in Korea
  • HYBE Invests Additional 104 Billion Won in SM Entertainment – Why?


Confirmed: Conditions & Schedule of Block Deals Pre-Disclosure Rules in Korea

By Sanghyun Park

  • Insiders must disclose transaction details, complete deals within 30 days, limit deviations to 30%, and submit disclosures 30 days before transactions.
  • Financial investors, including institutional ones, are exempt. This encompasses local pension funds (including NPS) and foreign financial investors. Deals under 1% of total shares and less than ₩5B are exempt.
  • Confirmation of the timeline indicates many block deals before July. We should hunt potential deals for proactive setups. Also, we should monitor basis widening in futures due to short-selling ban.

HYBE Invests Additional 104 Billion Won in SM Entertainment – Why?

By Douglas Kim

  • After the market close, it was announced that HYBE (352820 KS) acquired a 3.7% stake (868,948 shares) in SM Entertainment Co (041510 KS) for 104.3 billion won.
  • HYBE’s acquisition of shares was accomplished through the exercise of a put option by SM Entertainment’s founder Lee Soo-Man. After this purchase, HYBE will own 12.6% stake in SM Entertainment. 
  • We like SM Entertainment at current levels. Valuations are attractive and there is a strong pipeline of new music/songs to be launched by its artists in 2Q 2024. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Tesla Motors, USD, OpenAI, Lyondellbasell Indu Cl A, VAALCO Energy, Vulcan Materials Co, Lands’ End Inc, Qurate Retail , Relmada Therapeutics , Express and more

By | Daily Briefs, United States

In today’s briefing:

  • Elon Musk Can’t Be Trusted. He Also Can’t Be Stopped, Apparently.
  • US Rates: Slowly but Surely, Pushing Back the QT Taper Timeline
  • Is OpenAI’s business model sustainable?
  • LyondellBasell Industries N.V.: 6 Biggest Catalysts Of Its Top-Line Growth In 2024 & Beyond!
  • VAALCO Energy (NYSE: EGY): Potentially Acquiring Producing Assets in Cote D’Ivoire?
  • Vulcan Materials: Rock On – [Business Breakdowns, EP.151]
  • LE: Shifting to A Returns Driven Model; Initiating LE With Buy Rating & $12 PT
  • Qurate Retail Inc (QRTEA) – Wednesday, Nov 29, 2023
  • Relmada Therapeutics Inc (RLMD) – Wednesday, Nov 29, 2023
  • EXPR: Snapping the Store: Clearing & Gearing


Elon Musk Can’t Be Trusted. He Also Can’t Be Stopped, Apparently.

By Vicki Bryan

  • Tesla Q1 must be tracking even worse than I expected based on the uptick in Elon Musk’s erratic behavior—his tell when bad news spirals out of control.
  • Wacko conspiracies, Putin propaganda, National security threat! At least he has his self-flattering alter ego Adrian Dittmann to boost his spirits. 
  • Musk’s companies continue to rack up safety violations, government investigations, and lawsuits, while he loses his massive pay package and tries to dodge the SEC investigation into his Twitter acquisition.

US Rates: Slowly but Surely, Pushing Back the QT Taper Timeline

By At Any Rate

  • The Federal Reserve was expected to announce tapering of quantitative tightening (QT) in March and implement it in April, but recent minutes suggest a more relaxed approach with no urgency to start the process soon.
  • SOFR rates have trended lower in January, easing concerns over upward pressure, and there is plenty of liquidity in the marketplace, with significant RRP and reserve balances.
  • Forecasting for the Fed’s balance sheet evolution suggests a less volatile TGA balance and a shift in the relationship between t-bill issuance and RRP balances, leading to a more stable scenario for reserves in the near term.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Is OpenAI’s business model sustainable?

By Behind the Money

  • OpenAI, founded in 2015 as a nonprofit research lab, has transitioned into a for-profit entity with ambitious goals of creating artificial general intelligence to benefit humanity.
  • The company’s CEO, Sam Altman, is focused on solving the problem of super intelligence and has plans to set up his own semiconductor manufacturing pipeline and extend human lifespan.
  • OpenAI’s business model now involves catering to enterprise customers to generate revenue, and they face challenges in balancing their grand mission with the need for significant investment.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


LyondellBasell Industries N.V.: 6 Biggest Catalysts Of Its Top-Line Growth In 2024 & Beyond!

By Baptista Research

  • Upon evaluation of LyondellBasell’s Q4 and full-year 2023 results, a finely balanced investment thesis can be derived, considering the company’s strategic initiatives, performance, and the broader economic environment.
  • LyondellBasell safely navigated a challenging year, as illustrated in its outcome of earning $8.65 per share and a robust EBITDA of $5.2 billion.
  • The company’s cash generation was commendable, marked at $4.9 billion from operations, validating its efficient cash conversion ratio of 98%.

VAALCO Energy (NYSE: EGY): Potentially Acquiring Producing Assets in Cote D’Ivoire?

By Auctus Advisors

  • VAALCO is in discussions with Svenska Petroleum Exploration regarding a possible corporate transaction to acquire Svenska, whose primary asset is a 27.39% interest in Block CI-40, offshore Cote d’Ivoire.
  • Current working interest production is approximately 4,500 boe/d net to Svenska.
  • In 2022, Svenska generated after tax cashflow (before changes in working capital) of ~US$115 mm.

Vulcan Materials: Rock On – [Business Breakdowns, EP.151]

By Business Breakdowns

  • Vulcan Materials is America’s largest producer of construction aggregates, providing the foundation for buildings, roads, and infrastructure.
  • The company owns over 400 quarries located within 60% of the US population, producing aggregates used in asphalt and concrete.
  • The industry structure involves owning quarries and crushing rocks down to create materials used in various construction projects, with a market size of around $35 billion.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


LE: Shifting to A Returns Driven Model; Initiating LE With Buy Rating & $12 PT

By Small Cap Consumer Research

  • We are initiating coverage of Lands’ End, Inc., a leading solutions-based retailer of casual apparel, swimwear, outerwear, accessories, footwear and home products under the Lands’ End label, and school uniforms and workwear under the Lands’ End Outfitters brand, with a Buy rating and $12 price target, or 8.1X our FY24 (January) Adjusted EBITDA projection.
  • Under new CEO Andrew McLean, Lands’ End has shifted to a more returns driven business model, with a focus on offering key customer solutions, reducing inventory and discounting levels, shifting lower margin products to the licensing model, and expanding into key digital marketplaces, resulting in higher margins and cash flow.
  • With Lands’ End projected to shift into an EPS driven mode in FY24 and beyond, we believe the risk/reward in LE has materially improved, and we are initiating coverage of LE with a Buy rating and $12 price target.

Qurate Retail Inc (QRTEA) – Wednesday, Nov 29, 2023

By Value Investors Club

Key points

  • Qurate Retail’s capital structure is being optimized through buying back bonds to reduce leverage
  • The equity is viewed as a low-cost call option due to the company’s 35% annual growth in OIBDA
  • Despite industry concerns, QRTEA is positioned as a market leader in a growing sector, making it an attractive investment option.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Relmada Therapeutics Inc (RLMD) – Wednesday, Nov 29, 2023

By Value Investors Club

Key points

  • RLMD is a biotech company with a high-stakes binary outcome in 2024 for their antidepressant, REL-1017
  • Despite previous phase 3 trial failures, the drug has a validated mechanism of action and promising phase 2 data, leading to a $1.1B valuation
  • The stock is undervalued and presents a compelling investment opportunity with significant upside potential, especially through underpriced options for exposure to the outcome in mid-2024

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


EXPR: Snapping the Store: Clearing & Gearing

By Small Cap Consumer Research

  • We are reiterating our Buy rating, price target and projections for Express after visiting stores in Connecticut and Long Island.
  • With the stores receiving early Spring shipments, the focus is on the final clearance of older goods and setting up for the new Spring Season.
  • The new Spring season for women is setting up for lighter colors, continued high levels of versatility, and further expansion of key categories such as denim and Body Contour and women’s suiting, while for men the focus is on textured and patterned tops, denim and seasonal suiting and dress shirts, with the relaunch of performance long sleeve shirts.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Renesas Electronics, Welcia Holdings, Toshiba Corp, Aozora Bank Ltd, Tsuruha Holdings, RENOVA Inc, Tokyo Metro and more

By | Daily Briefs, Japan

In today’s briefing:

  • Renesas (6723) – YET ANOTHER Clean-Up Block Trade – This Time Mitsubishi Elec
  • Tsuruha (3391) And Welcia (3141) – Aeon Tsuruha Stake Buy Followed by Merger! [Redux]
  • Beyond the Bubble: A Deep Dive into the Forces Behind the Nikkei Index Surge
  • Aozora Bank (8304 JP): Murakami Becomes a Substantial Shareholder
  • JAPAN ACTIVISM:  Is Murakami-San Going To Do A PacMetals Rug Pull on Aozora? Or Is This For Real?
  • Renesas Electronics Block – Smaller than Recent Deals but Still Likely Well Flagged
  • Aeon (8267 JP), Tsuruha (3391 JP) And Welcia (3141 JP)’s Long-Dated Plan
  • Quiddity JPX-Nikkei 400 Rebal 2024: End-Feb 2024 Estimates
  • Aeon (Maybe) Gets Tsuruha, Could Trigger Wave of Mergers in the Sector (And Beyond)
  • Tokyo Metro IPO Early Look – Could Raise Around US$2bn While Still Recovering from COVID


Renesas (6723) – YET ANOTHER Clean-Up Block Trade – This Time Mitsubishi Elec

By Travis Lundy

  • Today after the close, Mitsubishi Electric (6503 JP) announced the sale of its position in Renesas Electronics (6723 JP). That’s 50,706,800 shares.  
  • This is the third large block in four months (Renesas in November for 223mm shares, NEC and Hitachi in January 2024 for 123mm shares).
  • This is smaller, and reasonably well-flagged. Index demand is longer-dated.

Tsuruha (3391) And Welcia (3141) – Aeon Tsuruha Stake Buy Followed by Merger! [Redux]

By Travis Lundy

  • The first piece had a question mark in the title. This one has an exclamation point. The exclamation point has value for one investor. Other people? Not so much.
  • Today post-close we got the deal. I was a little surprised it came this fast, but it’s now mostly done it appears – largely as predicted in the last piece.
  • There are things one can probably read into the details. It is probably worth thinking about those, and how those details affect the industry. 

Beyond the Bubble: A Deep Dive into the Forces Behind the Nikkei Index Surge

By Nimish Maheshwari

  • Japan’s Nikkei Stock Average has surged past its 1989 peak, fueled by global investor interest, corporate reforms, and innovative investment initiatives like the Nippon Individual Savings Account (NISA).
  • This resurgence marks a significant milestone in Japan’s economic landscape, reflecting renewed investor confidence, structural reforms, and potential growth opportunities in the market.
  • The Nikkei’s surpassing of its previous peak signals a shift in perception towards Japan’s market potential, prompting investors to reconsider the country’s economic trajectory and explore new avenues for investment.

Aozora Bank (8304 JP): Murakami Becomes a Substantial Shareholder

By Arun George

  • Murakami’s entity, City Index Eleventh, reported a 5.42% shareholding in Aozora Bank Ltd (8304 JP). Murakami started buying a day after the disastrous 3QFY23 results.
  • Murakami’s average buy-in price is JPY2,137.88 per share, a 34% discount to the pre-3QFY23 results share price. 
  • Murakami’s disclosure suggests two possibilities: the start of an activist campaign or a short-term trading play replicating the Pacific Metals (5541 JP) playbook.

JAPAN ACTIVISM:  Is Murakami-San Going To Do A PacMetals Rug Pull on Aozora? Or Is This For Real?

By Travis Lundy

  • Yesterday after the close, well-known Japanese activist Murakami-san’s preferred entity City Index Eleventh filed a Large Shareholder Report. 
  • The blast across Bloomberg was “*AOZORA 5.4% STAKE REPORTED BY CITY INDEX ELEVENTH.” Sounds exciting after the shares dropped 34% in two days earlier this month after reporting big writedowns. 
  • But there has to be a question here. Why? And Why this way? And what kind of activism would be possible? 

Renesas Electronics Block – Smaller than Recent Deals but Still Likely Well Flagged

By Ethan Aw

  • Mitsubishi Electric (6503 JP) is looking to raise approximately US$800m through an accelerated secondary block deal, via selling 50.71m shares (2.6% of TSO) of Renesas Electronics (6723 JP) stock. 
  • The deal will be an easy one to digest at only three days of three month ADV.
  • In this note, we will talk about the placement and run the deal through our ECM framework.

Aeon (8267 JP), Tsuruha (3391 JP) And Welcia (3141 JP)’s Long-Dated Plan

By Arun George

  • Aeon Co Ltd (8267 JP), Tsuruha Holdings (3391 JP) and Welcia Holdings (3141 JP) have announced an alliance to establish the largest drugstore alliance in Japan by December 2027.
  • Aeon will carry out several Tsuruha transactions – buy Oasis 13.58% stake at JPY15,500 per share and, on receiving regulatory approval, reach 27.17% of the voting rights.  
  • The agreements involve merging Tsuruha and Welcia through a share exchange offer and Aeon subsequently increasing its Tsuruha voting rights from 27.17% to less than 51%. 

Quiddity JPX-Nikkei 400 Rebal 2024: End-Feb 2024 Estimates

By Janaghan Jeyakumar, CFA

  • JPX-Nikkei 400 is composed of common stocks listed on the Tokyo Stock Exchange. It is a free-float-adjusted market-value-weighted (capped) index composed of 400 constituents.
  • A periodic review is conducted by the Index providers, the JPX Group and Nikkei Inc, in August every year. We look at the rankings of the potential ADDs/DELs every month.
  • Below is a look at potential ADDs/DELs for the JPX-Nikkei 400 index rebal event to come in August 2024 based on trading data as of end-February 2024.

Aeon (Maybe) Gets Tsuruha, Could Trigger Wave of Mergers in the Sector (And Beyond)

By Michael Causton

  • Aeon will almost definitely increase its stake in Tsuruha Holdings, which on its own will catalyse drugstore competitors to consider their mergeable options.
  • Tsuruha MAY merge with Welcia under Aeon and just talk of this will catalyse drugstore competitors even more.
  • But the ongoing fusion of drugstore retailing and FMCG formats like supermarkets and convenience stores, will also spur the entire FMCG sector to respond to Aeon’s massive potential dominance.

Tokyo Metro IPO Early Look – Could Raise Around US$2bn While Still Recovering from COVID

By Sumeet Singh

  • Tokyo Metro (TKYMETRO JP)’s shareholders, the Japanese and Tokyo Metropolitan Governments, could look to raise up to US$2bn by selling half of their stake via an IPO.
  • Tokyo Metro is one of the two metro network operators in the Tokyo region. It operates nine subway lines.
  • In this note, we take an early look at the possible listing.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: CK Asset Holdings, New World Development, Beijing Capital International Airport (BCIA), NetEase , Li Auto , Alibaba Group Holding , Sinotrans, Hangzhou Jiuyuan Gene Engineering and more

By | China, Daily Briefs

In today’s briefing:

  • Hong Kong To Scrap All “Spicy Measures” (Property Cooling Measures)
  • Hong Kong: Stamp Duties Axed; Mortgage Rules Relaxed
  • China Airports: Beijing Capital Airport Offers Best Risk/Return Payoff
  • Tencent/Netease: Approval Rotation to Netease in Feb
  • [Li Auto Inc. (LI US, BUY, TP US$52) TP Change]: What Can Go Wrong & Go Right in LI Becoming BYD #2
  • Alibaba Group Holdings: EM Fund Positioning Update
  • Sinotrans (598.HK), a Shining Example of SOE Reform
  • Pre-IPO Hangzhou Jiuyuan Gene Engineering – Old Pipelines Are Difficult to Bring New Breakthroughs


Hong Kong To Scrap All “Spicy Measures” (Property Cooling Measures)

By Travis Lundy

  • RTHK just reporting that HK Finance Secretary Paul Chan has said in his budget speech that HK will remove all property cooling measures in place, with immediate effect. 
  • That would be That is Special Stamp Duty, Buyer’s Stamp Duty, New Residential Stamp Duty. “Measures no longer necessary given the current economic and market conditions.”
  • This should cause people to get excited short-term about property developers.

Hong Kong: Stamp Duties Axed; Mortgage Rules Relaxed

By David Blennerhassett

  • Hong Kong residential property prices declined 7% in 2023 and are down >20% from the 2021 peak in 2021. The average price of offices also declined ~7% in 2023.
  • Scrapping property cooling measures, such as the special stamp duty applied to homes resold within 24 months, have been rumoured, to push up housing prices. 
  • In today’s annual budget, we got those. And then some. 

China Airports: Beijing Capital Airport Offers Best Risk/Return Payoff

By Eric Chen

  • Recent newsflow and company results suggest China outbound travel is on track to recover to pre-pandemic level by the end of this year.
  • China airports have different exposures to outbound travel, which largely determines the scale of their duty-free shopping business and earnings upside amidst this recovery cycle.
  • Beijing Capital Airport offers best risk/return profile among listed China airports in our view as current valuation does not fully capture even a conservative scenario of recovery in outbound travel.

Tencent/Netease: Approval Rotation to Netease in Feb

By Ke Yan, CFA, FRM

  • China announced game approval for the Feb batch. The number of games approved remained at a higher level than 2023.
  • The pace of China game approval appears to be accelerating, to the same level as pre-tightening.
  • Netease gets one game approved but we don’t see that the acceleration of game approval benefits big names proportionally.

[Li Auto Inc. (LI US, BUY, TP US$52) TP Change]: What Can Go Wrong & Go Right in LI Becoming BYD #2

By Eric Wen

  • LI Auto reported C4Q23 top line, non-GAAP operating profit and GAAP net income (6.2%), 13% and 81% vs. our estimates and 4.9%, 52% and 102% vs. consensus.
  • We believe LI can beat our delivery estimate on exports, but can also miss the consensus on gross margins if its 2024 volume target is met by sedans;
  • We raise our TP by US$5 to US$52 and reiterate BUY.

Alibaba Group Holdings: EM Fund Positioning Update

By Steven Holden

  • Despite average weights falling from over 6% in 2020 to under 2% today, 73% of EM funds remain invested in Alibaba.
  • The make up of the investor base has changed, with a rotation between high growth investors (out) and Value investors (in).
  • Of the 73% of current holders, the core portfolio weight range sits between 1.5% and 3%, with the most bullish topping out at 5%+

Sinotrans (598.HK), a Shining Example of SOE Reform

By Rikki Malik

  • A Profit-Oriented State Owned Enterprise that is walking the walk.
  • Management incentives are aligned with shareholders, a rarity in China.
  • Plenty of upside remains despite the market outperformance to date

Pre-IPO Hangzhou Jiuyuan Gene Engineering – Old Pipelines Are Difficult to Bring New Breakthroughs

By Xinyao (Criss) Wang

  • Jiuyuan is not a typical innovative pharmaceutical enterprise with cutting-edge technology. The current seemingly good revenue/profit performance is actually based on some old products from over a decade ago.
  • The risk of VBP could lead to a significant decrease in profit margins at any time. The cyclical changes in heparin industry would put more pressure on Jiuyuan’s performance.
  • As Jiuyuan has not yet demonstrated superior clinical data in Jikeqin for overweight/obesity indication, together with fierce competition, we are cautious about the performance in GLP-1s pipeline at this stage.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Toei Animation, Hyundai Electric & Energy, Tongcheng Travel Holdings , Rakuten Group , Li Auto , Outsourcing Inc, Samsonite, Ecopro BM , Sfa Engineering and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Toei Animation (4816 JP) – This Offering Could Be Heavy; the NEXT Offering Is More Interesting
  • KOSPI Size Indices – Potential Migrations as Focus Is on Price to Book
  • Final Flows for Hang Seng, HSCEI, HS Tech on 1 March Rebal
  • Rakuten’s New “Bond-Type Share” Issuance – Quite Quirky to Quantulate Rakuten’s Quisquous New Quoz
  • HSI, HSCEI, HSTECH, HSIII: Rebalance Flows Post Capping (Mar 2024)
  • Outsourcing (2427) MBO Arrives! Bain Launches Cheeky, Opportunistic, Low(Priced) TOB
  • Samsonite (1910 HK): Leader Of The Pack
  • Ecopro BM KOSPI Transfer Listing Disclosure
  • Block Deal Sale of 5% Stake In SFA Engineering by Samsung Display
  • Outsourcing (2427 JP): Relief as Bain Launches Tender at Unchanged Terms


Toei Animation (4816 JP) – This Offering Could Be Heavy; the NEXT Offering Is More Interesting

By Travis Lundy


KOSPI Size Indices – Potential Migrations as Focus Is on Price to Book

By Brian Freitas

  • The review period for the March rebalance of the KOSPI Size Indices started 1 December and will end 29 February. The changes will be implemented at the close 14 March.
  • We see 3 migrations from MidCap to LargeCap, 4 new adds to LargeCap, 7 migrations from LargeCap to MidCap, and 11 migrations from SmallCap to MidCap.
  • On average, stocks migrating from SmallCap to MidCap have the lowest price to book value and have historically outperformed stocks migrating between other categories.

Final Flows for Hang Seng, HSCEI, HS Tech on 1 March Rebal

By Travis Lundy

  • The Hang Seng Index, HSCEI, and HS Tech rebals were announced on 16 Feb. Janaghan Jeyakumar, CFA had expected GDS out, Tongcheng Travel in on HSTECH, along with the…
  • …deletion of Zhongsheng Group (881 HK) in HSCEI, with a low conviction replacement of Zijin Mining, which turned out to be an add of China Unicom Hong Kong (762 HK)
  • No changes to the main HSI Index, which means evolution is further delayed. Today was the day to recap the caps. Mar1 Flow estimates are included below for all three.

Rakuten’s New “Bond-Type Share” Issuance – Quite Quirky to Quantulate Rakuten’s Quisquous New Quoz

By Travis Lundy

  • Today, Rakuten Group (4755 JP) announced it would propose an amendment to its Articles at the AGM (28 March) to issue “Bond-Type Class Shares.”   First reaction: You wot, mate?
  • The company states it wants to “strengthen its financial base through reducing interesting-bearing debt by equity-related financings and conduct proactive control of debt maturity schedule, etc.”
  • Now it wants to issue listed bond-type shares. Dividends not interest. The last Japanese issuer of something similar was NEC in 2001. Few will remember, so we study the situation.

HSI, HSCEI, HSTECH, HSIII: Rebalance Flows Post Capping (Mar 2024)

By Brian Freitas


Outsourcing (2427) MBO Arrives! Bain Launches Cheeky, Opportunistic, Low(Priced) TOB

By Travis Lundy

  • After an extension due to a European Foreign Subsidies Review filing, and a small ‘accident’ regarding the earnings release, we have a deal. 
  • The earnings release itself seemed more innocuous than articles and rumour suggested show the causes of impairments and so it seemed like there was little cause to walk/declare MAC.
  • Now it will be done in 20 days. I still think this is cheeky, opportunistic, and low, and it is up to the float to decide what to do.

Samsonite (1910 HK): Leader Of The Pack

By David Blennerhassett

  • Luggage maker Samsonite (1910 HK) is up 11.8% today, as I type, after Bloomberg reported it is working with advisers as it studies possibilities, including going private.
  • With the reopening of China and the ongoing recovery in travel globally, Samsonite’s net sales improved markedly across all regions. 1H23 profit gained 185.3% versus 1H22.
  • FY23 figures should be out in the middle of next month.

Ecopro BM KOSPI Transfer Listing Disclosure

By Sanghyun Park

  • The schedule includes submitting the transfer listing application post-EGM on March 26th. KRX approval expected in 4-6 weeks due to Ecopro BM’s financial soundness. KOSPI listing follows in 2-3 weeks.
  • As for KOSDAQ 150 ad-hoc change, it will be replaced with the top reserved issue. The anticipated timing for this ad-hoc change is around mid or late May.
  • Following Feb 7 disclosure, stock surged over 10% in 2 days. Precedents show rallies pre-shareholder meetings, but KOSPI listing brings corrections. Today’s resolution could boost Ecopro BM short term.

Block Deal Sale of 5% Stake In SFA Engineering by Samsung Display

By Douglas Kim

  • After the market close on 27 February, Samsung Display announced that it will sell its 4.95% stake in Sfa Engineering (056190 KS) in a block deal sale. 
  • We would take the trade. We like the relatively large block deal sale discount as well as the company’s attractive valuations. 
  • SFA Engineering is trading at P/E of 8.3x, EV/EBITDA of 2.7x, and P/B of 0.7x in 2024, which are much lower than historical valuations.

Outsourcing (2427 JP): Relief as Bain Launches Tender at Unchanged Terms

By Arun George

  • Outsourcing Inc (2427 JP) announced that the pre-condition was satisfied, and Bain’s tender offer remains unchanged at JPY1,755 per share, a 52.1% premium to the undisturbed (8 December).
  • Shareholders will breathe a sigh of relief as the weak 4Q and significant impairments have raised concerns that Bain would cut its offer or walk away.
  • The offer attractiveness has increased partly due to lower consensus. At the last close and for a 3 April payment, the gross/annualised spread is 2.0%/22.8%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Utilities: Engie SA and more

By | Daily Briefs, Utilities Sector

In today’s briefing:

  • Quiddity Leaderboard ES50 Sep 24: The Race for Europe’s Big Index Flows


Quiddity Leaderboard ES50 Sep 24: The Race for Europe’s Big Index Flows

By Janaghan Jeyakumar, CFA

  • The ES50 Index is one of the most highly-tracked indices in Europe and the annual index review takes place in September every year.
  • This annual index rebal event usually results in some of the most significant index flow events in Europe every year typically amounting to billions of dollars.
  • In this insight, we take an early look the names leading the race to become ADDs/DELs for the upcoming index review in September 2024.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Outsourcing Inc, Ecopro BM , Cathay Pacific Airways, MTAR Technologies, Comfortdelgro Corp, Air China Ltd (H), Illinois Tool Works and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Outsourcing (2427) MBO Arrives! Bain Launches Cheeky, Opportunistic, Low(Priced) TOB
  • Ecopro BM KOSPI Transfer Listing Disclosure
  • Outsourcing (2427 JP): Relief as Bain Launches Tender at Unchanged Terms
  • Ecopro BM (247540 KS): Index Impact of KOSDAQ to KOSPI Transfer
  • Ecopro BM: Announces It Will Switch Listing from KOSDAQ to KOSPI
  • Cathay Pacific – Reported Air China Interest Prompts Assessment of Structural Disadvantages
  • MTAR Technologies- Forensic Analysis
  • Comfortdelgro (CD): March on Chinese Tourists
  • Air China (753 HK): Up Stakes in CX?
  • Illinois Tool Works: A Diversified


Outsourcing (2427) MBO Arrives! Bain Launches Cheeky, Opportunistic, Low(Priced) TOB

By Travis Lundy

  • After an extension due to a European Foreign Subsidies Review filing, and a small ‘accident’ regarding the earnings release, we have a deal. 
  • The earnings release itself seemed more innocuous than articles and rumour suggested show the causes of impairments and so it seemed like there was little cause to walk/declare MAC.
  • Now it will be done in 20 days. I still think this is cheeky, opportunistic, and low, and it is up to the float to decide what to do.

Ecopro BM KOSPI Transfer Listing Disclosure

By Sanghyun Park

  • The schedule includes submitting the transfer listing application post-EGM on March 26th. KRX approval expected in 4-6 weeks due to Ecopro BM’s financial soundness. KOSPI listing follows in 2-3 weeks.
  • As for KOSDAQ 150 ad-hoc change, it will be replaced with the top reserved issue. The anticipated timing for this ad-hoc change is around mid or late May.
  • Following Feb 7 disclosure, stock surged over 10% in 2 days. Precedents show rallies pre-shareholder meetings, but KOSPI listing brings corrections. Today’s resolution could boost Ecopro BM short term.

Outsourcing (2427 JP): Relief as Bain Launches Tender at Unchanged Terms

By Arun George

  • Outsourcing Inc (2427 JP) announced that the pre-condition was satisfied, and Bain’s tender offer remains unchanged at JPY1,755 per share, a 52.1% premium to the undisturbed (8 December).
  • Shareholders will breathe a sigh of relief as the weak 4Q and significant impairments have raised concerns that Bain would cut its offer or walk away.
  • The offer attractiveness has increased partly due to lower consensus. At the last close and for a 3 April payment, the gross/annualised spread is 2.0%/22.8%.

Ecopro BM (247540 KS): Index Impact of KOSDAQ to KOSPI Transfer

By Brian Freitas

  • Ecopro BM (247540 KS)‘s Board has approved the delisting of the stock from the KOSDAQ market and to list on the KOSPI market. The shareholder meeting is on 26 March. 
  • Historically, the KRX has taken an average of 64 days from application to approve the listing to transfer from the KOSDAQ market to the KOSPI market.
  • Ecopro BM (247540 KS) will be deleted from the KOSDAQ 150 Index on its last trading day and inclusion in the KOSPI 200 Index could take place in September.

Ecopro BM: Announces It Will Switch Listing from KOSDAQ to KOSPI

By Douglas Kim

  • After the market close on 27 February, Ecopro BM (247540 KS) announced that it will switch its listing from KOSDAQ to KOSPI. 
  • Ecopro BM currently has a market cap of 23.1 trillion won. It is the largest stock in KOSDAQ right now and it would be the 17th largest stock in KOSPI.
  • Lofty valuation is one of the main reasons why we continue to be bearish on Ecopro BM. It is trading at P/E of 203x in 2024 and 71x in 2025.

Cathay Pacific – Reported Air China Interest Prompts Assessment of Structural Disadvantages

By Neil Glynn

  • We publish a deep dive on historical margin management at Cathay Pacific following Bloomberg reports that Air China is considering raising its 29.99% stake.
  • We see Cathay’s consistent underperformance of the global industry as due to structural disadvantages competing against lower cost competitors without the benefit of attractive joint ventures or M&A.
  • Our deep dive comparing margin generation to ten major global peers highlights weak pricing power without sufficient offset from staff cost/other cost efficiencies as the key problem.

MTAR Technologies- Forensic Analysis

By Nitin Mangal

  • MTAR Technologies (MTARTECH IN)  is a precision engineered company that caters to customers in clean energy, Space, Defense sectors, etc. 
  • The company has done well over the last few years in terms of securing business, however there are concerns on the margins end, working capital and cash generation. 
  • There also exists a high business risk in terms of customer concentration since more than 75% of the revenues (F23) come from one single entity.

Comfortdelgro (CD): March on Chinese Tourists

By Henry Soediarko

  • Comfortdelgro Corp (CD SP) share price has underperformed its tourism related transport operator peers.
  • Key drivers are still strong, including the expected influx of Chinese tourists from visa-free travel arrangements.
  • Valuation is still compelling, and it is not too late to own it.

Air China (753 HK): Up Stakes in CX?

By Osbert Tang, CFA

  • Speculations on Air China Ltd (753 HK) seeking control of Cathay Pacific (293 HK) reappeared recently. We think a change in CX’s ownership is just a matter of time.
  • CX has been a more important profit contributor to Air China after the pandemic, and depends on pricing, Air China is expected to benefit from such acquisition.
  • Both are trading on 0.5SD below their 5-year P/B average and we prefer CX in the short term, but Air China looks to be a better long-term choice. 

Illinois Tool Works: A Diversified

By Baptista Research

  • Generators and machine producer, Illinois Tool Works Inc.
  • (ITW) has reported a modest growth amidst the unique operational challenges faced in the fourth quarter of 2023.
  • In particular, the company confronted reduced demand for capital expenditure (CapEx), lean customer inventories and a strike within the automotive industry.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Energy/Materials: HD Hyundai , Adbri, ADF Group , Ecolab Inc, Phillips 66 and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • Constituents of the 1st Corporate Value Up ETF in Korea
  • Adbri (ABC AU): CRH and Barro’s Binding A$3.20 Offer
  • DRX: Increasing Target Price on Improved Outlook
  • Ecolab Inc: Successful Pricing Initiatives and Delivered Product Costs (DPC) Management! – Major Drivers
  • Phillips 66: Is The Demand Recovery In The Refining Macro Enough To Warrant A Bullish Thesis? – Major Drivers


Constituents of the 1st Corporate Value Up ETF in Korea

By Douglas Kim

  • Samsung Active Management launched the first Corporate Value Up ETF called KoAct Dividend Growth Active ETF on 27 February. It also revealed some of the major constituents of this ETF.
  • Samsung Active Management revealed the top 20 constituents of this ETF, which comprised 73.2% of the total ETF AUM.
  • In the coming weeks, there will be many other Corporate Value Up related ETFs that will be created that are similar to Samsung’s KoAct Dividend Growth ETF. 

Adbri (ABC AU): CRH and Barro’s Binding A$3.20 Offer

By Arun George

  • Adbri (ABC AU) has entered a scheme implementation deed with CRH (CRH US) and Barro at A$3.20 per share, a 41.0% premium to the undisturbed price of A$2.27 (13 December).
  • The offer requires shareholder and FIRB approval. FIRB approval for the bidder, CRH, should be forthcoming as it is a Fortune 500 company with HQ in Ireland. 
  • The offer is attractive vs. peer multiples and historical ranges. At the last close and for a mid-June payment, the gross/annualised spread is 1.9%/6.6%.

DRX: Increasing Target Price on Improved Outlook

By Atrium Research

  • We are revisiting the assumptions in our model for ADF following strong industry data and positive conversations with management. 
  • We are increasing our revenue and profitability estimates from Q4 onward to reflect the more bullish outlook.
  • We have increased our target multiple to 6.5x FY25 EBITDA (previously 6.0x), leading to a new $13.00/share target price (previously $10.00/share).

Ecolab Inc: Successful Pricing Initiatives and Delivered Product Costs (DPC) Management! – Major Drivers

By Baptista Research

  • Ecolab Inc., during their latest earnings, highlighted strong growth in their fourth quarter performance for 2023, solidifying a favorable year for the company.
  • Despite unstable macroeconomic conditions, the team drove value-based pricing while consistently maintaining strong business momentum.
  • Their success arose from creating value for customers by enhancing operational performance, as well as reducing water and energy consumption.

Phillips 66: Is The Demand Recovery In The Refining Macro Enough To Warrant A Bullish Thesis? – Major Drivers

By Baptista Research

  • Phillips 66 delivered a strong performance in the fourth quarter and for the full year 2023.
  • It reported a total shareholder return of 33% in 2023 and also increased its quarterly dividend by 8%.
  • The company highlighted its diversified and integrated portfolio as a key aspect of its business strategy, claiming that it delivered strong returns on capital employed and a high payout ratio backed by dividend growth.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Sfa Engineering, Baidu, NVIDIA Corp, Epam Systems and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Block Deal Sale of 5% Stake In SFA Engineering by Samsung Display
  • [Baidu, Inc. (BIDU US, BUY, TP US$146)TP Change]: The Commercialization Path of AI Is Becoming Clear
  • IFS Connect Takeaways | Nvidia Earnings as the New Semiconductor King
  • EPAM Systems: Will The Strong Demand Generation From 2023 Continue In 2024 & Beyond? – Major Drivers


Block Deal Sale of 5% Stake In SFA Engineering by Samsung Display

By Douglas Kim

  • After the market close on 27 February, Samsung Display announced that it will sell its 4.95% stake in Sfa Engineering (056190 KS) in a block deal sale. 
  • We would take the trade. We like the relatively large block deal sale discount as well as the company’s attractive valuations. 
  • SFA Engineering is trading at P/E of 8.3x, EV/EBITDA of 2.7x, and P/B of 0.7x in 2024, which are much lower than historical valuations.

[Baidu, Inc. (BIDU US, BUY, TP US$146)TP Change]: The Commercialization Path of AI Is Becoming Clear

By Ying Pan

  • We expect Baidu to report C4Q23 revenue, GAAP op. profit and GAAP net income inline, (2.3%) and (4.5%) vs. consensus.
  • The slight bottom-line miss was mainly attribute to the increased marketing costs related to user acquisition. Baidu cloud revenue is robust due to AI product stimulating demand. 
  • We cut our target price to US$146 for the spendings related to the construction of future e-commerce business but maintain BUY for its cheap valuation.

IFS Connect Takeaways | Nvidia Earnings as the New Semiconductor King

By The Circuit

  • Nvidia emerges as a strong challenger in the semiconductor industry, while intel remains the dominant player
  • Intel makes significant strides in its foundry business, showcasing a clear focus on advanced nodes like 18A and 14A
  • Intel positions itself as a serious player in the foundry market, attracting key customers like Microsoft and building a strong ecosystem around its offerings

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


EPAM Systems: Will The Strong Demand Generation From 2023 Continue In 2024 & Beyond? – Major Drivers

By Baptista Research

  • EPAM Systems had a challenging year in 2023 due to geopolitical factors – Russian invasion of Ukraine – which led to disruption and a rebalancing of their delivery platform across Europe, Western and Central Asia, India, and Latin America.
  • Despite these external disturbances, EPAM managed to perform creditably, underlining its ability to navigate a volatile demand environment.
  • EPAM’s activities in 2023 were largely focused on enhancing delivery quality, optimizing cost effectiveness, and leveraging their technological capabilities to tap into the future opportunities in Gen AI and AI. Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Immix Biopharma Inc, Bristol Myers Squibb Co, Eli Lilly & Co, Olympus Corp, OSE Immuno, Vertex Pharmaceuticals, West Pharmaceutical Services Inc, Boston Scientific, Xunfei Healthcare Technology and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Immix Biopharma – 2023 recap with a preview of active year ahead
  • Bristol-Myers Squibb: The Ongoing Growth Story Of Each Of Its Core Drugs! – Major Drivers
  • Eli Lilly & Company: Product pipeline evolution with focus on improved patient outcomes! – Major Drivers
  • Olympus Corp (7733 JP): Q3 Operating Profit Misses Estimates Despite Sales Beat; FY24 Guidance Cut
  • OSE Immunotherapeutics – Encouraging OSE-279 clinical update
  • Vertex Pharmaceuticals: Commercial Launch of CASGEVY
  • West Pharmaceutical Services: Regulatory Shift Driving Increased Demand for High Value Products! – Major Drivers
  • Boston Scientific Corporation: Axonics & Other Acquisitions Are Potential Game Changers? – Major Drivers
  • Pre-IPO Xunfei Healthcare Technology – Continuous Losses Will Be the Norm


Immix Biopharma – 2023 recap with a preview of active year ahead

By Edison Investment Research

IMMX has shared a 12-month recap, capturing key clinical and regulatory events from 2023, setting the stage for an active 2024. Its lead CAR-T asset (NXC-201) is a B-cell maturation antigen (BCMA) targeting therapy for amyloid light chain amyloidosis (ALA) and multiple myeloma (MM). The latest clinical data (Phase Ib/IIa NEXICART-1 trial) showed an overall response rate (ORR) of 100% in ALA patients (n=10) and 90% in MM patients (n=50). On the regulatory front, NXC-201 received Orphan Drug designation (ODD) in February 2024 from the EMA for ALA, and in Q323 from the FDA for ALA and MM. The FDA also cleared Immix’s Investigational New Drug (IND) application in Q423, permitting NXC-201 dosing at US trial sites (NEXICART-2 trial for ALA patients). We believe this is an important development step for NXC-201, and we look forward to rolling data readouts after the start of NEXICART-2, most likely in H124.


Bristol-Myers Squibb: The Ongoing Growth Story Of Each Of Its Core Drugs! – Major Drivers

By Baptista Research

  • Bristol-Myers Squibb (BMS) reported a strong fourth quarter for 2023 with sales momentum in both their established and new product portfolios, showing a growth of 9% and earning nearly $10 billion in revenue.
  • Multiple key brands, including Eliquis, Opdivo, Reblozyl, Opdualag, Breyanzi, Camzyos, and Sotyktu, contributed to this growth.
  • In addition, BMS generated significant cash flows from operations amounting to $4.3 billion.

Eli Lilly & Company: Product pipeline evolution with focus on improved patient outcomes! – Major Drivers

By Baptista Research

  • Eli Lilly and Company’s Q4 2023 earnings showed a year of growth and advancement for the company.
  • Revenue increased by 20 percent for the full year and 28 percent for the most recent quarter, as seen in the company’s newly launched portfolio gaining momentum.
  • Notably, the company received regulatory approvals for Zepbound, Jaypirca, Omvoh, Ebglyss in the EU, and an expanded label for Verzenio and two new indications for Jardiance within 2023.

Olympus Corp (7733 JP): Q3 Operating Profit Misses Estimates Despite Sales Beat; FY24 Guidance Cut

By Tina Banerjee

  • Olympus Corp (7733 JP) announced disappointing Q3FY24 result. Although revenue increased 7% YoY to ¥239B, beating estimate of ¥236B, operating profit declined 30% YoY to ¥34B, below estimate of ¥43B.
  • The company cut FY24 operating profit guidance for second time and reduced revenue guidance after raising it in November. Noto Peninsula earthquake is the main reason for reducing revenue guidance.
  • Although both revenue and profits are expected to improve in FY25, it will be difficult to achieve an operating margin of 20% and sales growth of 5%.

OSE Immunotherapeutics – Encouraging OSE-279 clinical update

By Edison Investment Research

At the 2024 ESMO Targeted Anticancer Therapies Congress, OSE Immunotherapeutics (OSE) presented encouraging interim results from the Phase I/II dose escalation and expansion study for OSE-279, its anti-PD1 monoclonal antibody. The data show promising preliminary efficacy in patients with advanced solid tumours with no therapeutics options available. The mono therapy has also continued to demonstrate a desirable pharmacokinetic/pharmacodynamic (PK/PD) profile and manageable safety. OSE is investigating various combination approaches, such as with its lead cancer vaccine Tedopi, which we believe could maximise the potential of its proprietary therapies. OSE has six ongoing clinical studies (across several indications) and three pre-clinical assets and, in our view, the most significant upcoming milestone for the company will be initiation of the confirmatory Phase III trial for Tedopi in second-line non-small cell lung cancer (Q224 in the US and extension to European sites in H224).


Vertex Pharmaceuticals: Commercial Launch of CASGEVY

By Baptista Research

  • During Vertex Pharmaceuticals’ Fourth Quarter 2023 Earnings Call, the company highlighted the achievements of the past year, including the strong financial results they achieved and the progress of their various drug development programs.
  • Vertex continued its impressive growth streak, achieving full year CF product revenues of $9.87 billion, which represents an 11% growth from 2022.
  • The company attributes this growth primarily to the increased number of CF patients being reached and the groundbreaking approvals of CASGEVY, the first-ever CRISPR/Cas9-based therapy.

West Pharmaceutical Services: Regulatory Shift Driving Increased Demand for High Value Products! – Major Drivers

By Baptista Research

  • West Pharmaceutical Services recently held its fourth quarter 2023 earnings conference call, closely examining their financial results, providing an update on their business operations, and presenting an overview of their financial outlook for the full year of 2024.
  • The company reported a significant base growth in 2023, which offset a decrease of COVID-19-related sales by about $320 million.
  • This growth was mainly driven by expanding customer demand for the company’s high value product offerings and their contract manufacturing services.

Boston Scientific Corporation: Axonics & Other Acquisitions Are Potential Game Changers? – Major Drivers

By Baptista Research

  • Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company’s history by surpassing set financial goals.
  • Throughout the year, total company operational sales grew by 15% and organic sales by 14%, exceeding the high-end guidance range of 8% to 10%.
  • Operational sales growth for the full year was registered at 13%, and organic sales grew by 12%.

Pre-IPO Xunfei Healthcare Technology – Continuous Losses Will Be the Norm

By Xinyao (Criss) Wang

  • In healthcare AI industry, the commercialization process is complex and burdened with challenges. Related products mainly plays an auxiliary role in medical scenarios, rather than a core support or rigid-demand. 
  • The idea of creating corresponding solutions for C-end and B-end customers by FUNFEI is not inappropriate. However, both B-end and C-end businesses of FUNFEI have encountered varying degrees of problems.
  • We’re not optimistic about XUNFEI’s profitability. The sluggish stock price performance after Airdoc’s listing indicates that the market/investors have not fully recognized healthcare AI enterprises, leading to low valuation.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars